购物车
- 全部删除
- 您的购物车当前为空
Ralimetinib selectively inhibits phosphorylation of MK2 (Thr334) and has no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Ralimetinib is an effective and selective, ATP-competitive inhibitor of p38 MAPK α/β (IC50s: 5.3 and 3.2 nM, respectively).
Ralimetinib selectively inhibits phosphorylation of MK2 (Thr334) and has no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Ralimetinib is an effective and selective, ATP-competitive inhibitor of p38 MAPK α/β (IC50s: 5.3 and 3.2 nM, respectively).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 7,000 | 5日内发货 | |
50 mg | ¥ 13,800 | 5日内发货 | |
100 mg | ¥ 17,500 | 5日内发货 |
产品描述 | Ralimetinib selectively inhibits phosphorylation of MK2 (Thr334) and has no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Ralimetinib is an effective and selective, ATP-competitive inhibitor of p38 MAPK α/β (IC50s: 5.3 and 3.2 nM, respectively). |
靶点活性 | p38α MAPK:5.3 nM, p38β MAPK:3.2 nM |
别名 | LY2228820 |
分子量 | 420.53 |
分子式 | C24H29FN6 |
CAS No. | 862505-00-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.